Pulmonary fibrosis is a chronic and progressive lung disease which results in a loss of pulmonary function and eventually respiratory failure. Inflammation and epithelial mesenchymal transition (EMT) play important roles in the pathogenesis of pulmonary fibrosis. This study aimed to investigate the therapeutic effect of polydatin (PD) in bleomycin-induced pulmonary fibrosis. A bleomycin-induced pulmonary fibrosis animal model used SD rats. Morphological changes were analyzed by hematoxylin-eosin staining. RT-qPCR and western blot were used for the detection of the expression of TGF-b1, collagen I, collagen III, Ecadherin, fibronectin and the ratios of p-Smad2/Smad2, p-Smad3/Smad3. The concentrations of PICP, PIIINP, TNF-a, IL-1b, IL-6 and IL-17 were measured by enzyme linked immunosorbent assay (Elisa) assay.
Introduction
Pulmonary brosis is a chronic and progressive lung disease which involves the gradual exchange of normal lung parenchyma with brotic tissue. Pulmonary brosis is characterized by broblast proliferation, excessive collagen accumulation and deposition of extracellular matrix (ECM) proteins which result in a loss of pulmonary function and eventually respiratory failure. 1 The etiology of pulmonary brosis is various, of which inammation is reported to play an important role in the pathogenesis of pulmonary brosis. 2 Transforming growth factor (TGF)-b1 is an important mediator involved in pulmonary inammation and the progression of brotic changes.
3,4 TGF-b1 can induce collagen deposition, increase ECM production, and increase a-smooth muscle actin (a-SMA) expression in lung tissue, which contribute to pulmonary brosis. 5, 6 Besides that, broblasts and myobroblasts which are involved in the repair of aberrant tissues and deposition of ECM components also play key roles in pulmonary brosis. 7 Fibroblasts and myo-broblasts proliferate during the progression of brosis, leading to the disorder of epithelial-mesenchymal cells. 8 In the patients with pulmonary brosis, approximately 80% of alveolar epithelial cells in the brotic loci express the mesenchymal marker a-SMA which is the feature of the epithelialmesenchymal transition (EMT). 9 Taken together, these nd-ings suggest that inammation and EMT may be potential key steps during pulmonary brosis, and inhibition of inamma-tion and EMT may be useful ways to ameliorate pulmonary brosis.
Polydatin (3,4 0 ,5-trihydroxystibene-3-b-mono-D-glucoside; PD), is a natural component extracted from perennial herb Polygonum cuspidatum and a traditional Chinese herbal medicine. 10 Previous studies indicated that PD exerted multiple biological activities including anti-inammation and antioxidation. Chen reported that PD attenuated kidney inam-mation by inhibiting NF-kB/NLRP3 inammasome activation.
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Moreover, Cao reported that PD alleviated radiation-induced lung injury through activation of Sirt3 and inhibition of EMT.
12 These studies revealed that PD had anti-inammation and anti-EMT effects, which might be an effective agent for the treatment of pulmonary brosis. However, investigations on whether PD can ameliorate pulmonary brosis are few and more studies are needed.
In our present study, we established pulmonary brosis animal model using Sprague-Dawley (SD) rats and explored the effect of PD on the pathogenesis of pulmonary brosis. We observed that PD ameliorated pulmonary brosis through suppressing inammation and EMT via inhibiting TGF-b/Smad signaling pathway.
Materials and methods

Reagents
Polydatin was obtained from the National Institutes for Food and Drug Control (purity >98%, HPLC; Beijing, China) (Fig. 1A) . Bleomycin was bought from Taihe Co, Tianjin, China. PD was purchased from TW Reagent Co., Ltd, Shanghai, China and dissolved in dimethyl sulfoxide (DMSO) at a stock solution of 10 mM and directly diluted in medium to appropriate concentrations prior to the experiments. PICP, PIIINP, TNF-a, IL-1b, IL-6 and IL-17 Elisa kits were obtained from Wuhan Boster Biological Technology Ltd., Wuhan, P. R. China. TGF-b was obtained from Sigma, St. Louis, MO, USA. Primary antibodies against E-cadherin, bronectin, p-Smad2, Smad2, p-Smad3, Smad3 and GAPDH were purchased from Cell Signalling Technology, CST, Beverly, Massachusetts.
Animals and induction of pulmonary brosis
Male, 4-6 weeks-old and weighing 180-220 g SD rats were provided by the Experimental Animal Center of The Third 13 Briey, rats were anaesthetized and then were cut in the middle of the neck skin. Trachea was exposed aer separation of subcutaneous tissue, muscle, and fat, and was punctured with a needle of 1 ml syringe. Bleomycin (4 mg ml À1 ) in saline solution was delivered into the trachea with a modied syringe needle in a dosage of 5 mg kg À1 body weight. The rats were rotated immediately aer receiving bleomycin to ensure an even drug distribution in the lung. Then the neck skin incision was sewn. Aer recovery from anesthesia, the rats were returned to their cages and allowed free access to food and water as normal. The rats were divided into 4 group with 6 mice in each group: (1) control group: normal and healthy SD rats without treatment; (2) sham group: rats received an operation and intratracheal instillation of the same volume of sterile saline; (3) model group: rats received an operation and a single intratracheal instillation of bleomycin; (4) PD treated group: rats received an operation and a combination with intratracheal instillation of bleomycin and intraperitoneal injection of PD (100 mg per kg per day) 28 days aer administration of single-dose bleomycin. The dose of PD was selected according to the literature 14 All rats (not model group) were sacriced aer 29 days of the bleomycin injection. The model group was sacriced on the 14th of bleomycin administration to validate bleomycin-induced lung brosis on the 14th of the experiment. 
Cell culture and treatment
Morphological analysis and histochemical staining
The grades of pulmonary inammation and brosis were analyzed by Hematoxylin-Eosin (HE) staining. Biopsies of lung tissues were xed with 10% paraformaldehyde in sterile phosphate-buffered saline and em-bedded in paraffin wax. Sections were cut at 5 mm thickness using a microtome and deparaffinized tissue sections were subjected to staining for histological examination. Sections were stained with HE to observe morphology changes as described before. 15 The slides were examined by light microscopy and photographed. Lung inammation and brosis were evaluated by Szapiel scoring method, a standard four point scoring scale for intensity, with each slide scored as 1, 2, 3 or 4.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) Total RNAs were extracted from lung tissues using TRIzol (Invitrogen; Thermo Fisher Scientic, Inc.) according to the manufacturer's protocol. PrimeScript RT reagent kit (Takara Bio, Inc., Otsu, Japan) was used for transcription from RNA to cDNA. qPCR was performed in a nal volume of 20 mL using a 2Â SYBR Green qPCR kit (Takara Bio, Inc., Otsu, Japan). The expression levels of TGF-b1, collagen I and collagen III were calculated using the 2 ÀDDCt method with GAPDH as an internal control for normalization.
Enzyme linked immunosorbent assay (Elisa) assay
Blood samples were collected from rats and the serum was separated. Procollagen type I carboxy-terminal peptide (PICP), procollagen type III aminoterminal peptide (PIIINP), TNF-a, IL1b, IL-6 and IL-17 in serum were determined by ELISA kits following the manufacturer's instructions.
Cell Counting Kit-8 (CCK-8) assay
CCK-8 assay was used for cell proliferation test. Cells were seeded into a 96-well plate with 2 Â 10 3 cells per well in triplicate. The CCK-8 reagent (Dojindo Molecular Technologies, Inc. Japan) was added in each well (5 mg ml À1 ) at indicated time points and then incubated in dark at 37 C for 2 h. Absorbance was determined at a wavelength of 450 nm.
Wound healing assay
HFL-1 cells (5 Â 10 5 ) were seeded into 6-well plates and incubated for 24 h. Aer reaching 90-100% conuence, a sterile pipette tip was used to create a straight scratch to form a wound. Aer washing with PBS twice, the cells were cultured for another 24 h. Mitomycin C (10 mg ml À1 ) was added to the cell culture medium to inhibit cell replication according to literature.
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Cells which migrated to the wounded area were visualized and images were captured, the percentage of wound closure was determined.
Western blot assay
Proteins were extracted from cells using RIPA lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China). The same amount of proteins were separated by 10% SDS-PAGE gel and then transferred into PVDF membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Aer blocking with 5% nonfat milk, the membranes were incubated with primary antibodies against E-cadherin (#14472, 1 : 1000, Cell Signalling Technology, CST, Beverly, Massachusetts), bronectin (ab2413, 1 : 1000, Abcam, Cambridge, UK), p-Smad2 (#18338, 1 : 1000, CST), Smad2 (#8685, 1 : 1000, CST), p-Smad3 (#9520, 1 : 1000, CST), Smad3 (#9523, 1; 1000, CST) and GAPDH (#5174, 1 : 1000, CST) respectively at 4 C overnight. Then the membranes were incubated with corresponding peroxidase-linked secondary antibodies at room temperature for 1 h. Signal detection was performed using an ECL system (Millipore, Billerica MA, USA).
Statistical analysis
Data was presented as the mean AE standard deviation (SD). Statistical signicance was performed using Student's t test or one-way ANOVA test with SPSS 19.0. The difference was considered statistically signicant at P < 0.05.
Results
PD relieves bleomycin-induced pulmonary brosis
Pulmonary brosis was induced by intratracheal administration of bleomycin in our study. As shown in Fig. 1B , in contrast to the normal alveolar morphology in control group and sham group, bleomycin treatment induced obvious alveolar wall thickening and massive inltration of leukocytes in the interstitium, resulting in higher alveolitis scores compared with control group and sham group. However, PD treatment ameliorated interstitial brosis, inltration of leukocytes and decreased alveolitis scores compared with model group significantly ( Fig. 1B and C, **P < 0.01, # P < 0.05). Moreover, the level of TGF-b1, collagen I, collagen III, PICP and PIIINP were brosis indicators according to previous reports, 17,18 thus, we detected the inuence of PD on these biomarkers in bleomycin-induced pulmonary brosis model. Results from RT-qPCR and Elisa showed that bleomycin up-regulated the expression of TGF-b1, collagen I, collagen III and induced the production of PICP and PIIINP while PD suppressed these bleomycin-induced increase signicantly (Fig. 1D -H, *P < 0.05, **P < 0.01, # P < 0.05). Our data indicated that PD relieved bleomycin-induced pulmonary brosis.
PD suppresses inammation in pulmonary brosis
As inammation plays an important role in the pathogenesis of pulmonary brosis. Report suggest that TNF-a, IL-1b, IL-6 and IL-17 were pro-inammatory cytokines/chemokines that was associated with lung injury. 19 Thus, we measured the expression of some inammation cytokines (TNF-a, IL-1b, IL-6 and IL-17) using Elisa assay. We observed that bleomycin induced the production of TNF-a, IL-1b, IL-6 and IL-17 compared with sham group. However, PD treatment inhibited the production of these inammation cytokines compared with model group ( Fig. 2A -D, *P < 0.05, **P < 0.01, # P < 0.05). These results suggested that PD suppressed inammation in pulmonary brosis.
PD inhibits EMT in pulmonary brosis
In vitro experiments were conducted using HFL-1 cells. The toxicological properties of polydatin were detected in HFL-1 cells. The results displayed that the cell viability was strongly (Fig. 3A) . Thus, we chose low dose (50 mM) and high dose (150 mM) PD for the following experiment. TGFb plays a crucial role in promoting EMT.
20 TGF-b was used to induce brosis of HFL-1 cells. The results showed that TGFb promoted migration of HFL-1 cells compared with control group. PD treatment suppressed the increased migration of HFL-1 cells induced by TGF-b in a dose-dependent manner (Fig. 3B and C, *P < 0.05, # P < 0.05). Besides that, TGFb decreased the expression of epithelial markers (E-cadherin) and increased the expression of bronectin, which has been reported serve to localize TGF-b1 signaling to drive EMT.
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While PD treatment had the opposite effects on the expression of E-cadherin and bronectin compared with TGF-b group dosedependently ( Fig. 3D -F, **P < 0.01, # P < 0.05, ## P < 0.01). Taken together, our results demonstrated that PD inhibited EMT in pulmonary brosis.
PD suppresses TGF-b/Smad signaling pathway in pulmonary brosis
TGF-b/Smad signaling pathway is reported to be involved in pulmonary brosis. 22 Therefore, we investigated relative protein level of Smad2, Smad3 which were key proteins in TGF-b/Smad signaling pathway and their phosphorylation level. The data indicated that TGF-b increased the level of TGF-b and the ratios of p-Smad2/Smad2 and p-Smad3/Smad3, suggesting that TGFb activated TGF-b/Smad signaling pathway during pulmonary brosis. However, PD decreased the level of TGF-b and the ratios of p-Smad2/Smad2 and p-Smad3/Smad3 compared with TGF-b group in a dose-dependent manner (Fig. 4A -C, **P < 0.01, # P < 0.05, ## P < 0.01). These results revealed that PD inhibited TGF-b/Smad signaling pathway in pulmonary brosis.
Discussion
Pulmonary brosis is a chronic and progressive lung disease around the world. Patients with pulmonary brosis are oen treated with immune suppressive agents combined with cytotoxic agents. However, these treatments can also cause numerous side effects including myelotoxicity and diffuse alveolar hemorrhage. 23 Therefore, to develop new drugs with better efficacy and tolerability against pulmonary brosis is urgently needed. In our present study, we found PD, a traditional Chinese herbal medicine, can ameliorate pulmonary brosis through suppressing inammation and EMT via inhibiting TGF-b/Smad signaling pathway.
Although there are several pulmonary brosis animal models induced by drag, radiation and bronchiolitis obliterans, it is still unclear whether these models can simulate the pulmonary brosis which is commonly seen in humans. However, the mouse model of bleomycin-induced pulmonary brosis which can represent human pulmonary brosis pathogenesis has gained much attention. The intratracheal bleomycin application promotes the release of pro-inammatory cytokines including TNF-a, IL-1b and IL-6 and induces acute lung inammation. 24 Hence, we used bleomycin-induced pulmonary brosis mouse model in our present study.
Human pulmonary brosis is characterized by broblast proliferation, excessive collagen accumulation and other deposition of ECM proteins in the pulmonary interstitial. Here we observed bleomycin treatment resulted in alveolar wall thickening and massive inltration of leukocytes in the interstitium, resulting in high alveolitis scores. Up-regulation of TGF-b1 contributes to the pathogenesis of bleomycin-induced pulmonary brosis. 25, 26 During pulmonary brosis, broblasts and myobroblasts were activated and could secrete collagens including collagen I and III, resulting in tissue remodeling and brosis formation.
27 PICP and PIIINP are widely recognized as biomarkers of brotic disease and are elevated in pulmonary brosis. 28 In agreement with previous studies, we found that bleomycin treatment increased the expression of TGF-b1, collagen I, collagen III and production of PICP and PIIINP signicantly, suggesting that bleomycin-induced pulmonary brosis animal model was conducted successfully in our study.
PD, which is a traditional Chinese herbal medicine abound in grape juices, has been found to exert multiple biological activities including anti-inammation, anti-oxidation and multiple-organ protection. Xu reported that PD attenuated D-galactose-induced liver injury.
29 PD also alleviated radiation-induced lung injury through activation of Sirt3 and inhibition of EMT.
12 Here, we observed that PD treatment ameliorated bleomycin-induced pulmonary brosis through reducing alveolitis scores, the expression of TGF-b1, collagen I, collagen III and production of PICP and PIIINP compared with model group, indicating that PD might be an effective agent to relieve pulmonary brosis.
The development of lung brosis is preceded by an increase accumulation of inammatory cells within the lung parenchyma and inammation cytokines play important roles in the initiation and progression of pulmonary brosis. Pulmonary brosis is associated with expression of inammatory mediators such as TNF-a, IL-1b and IL-17. [30] [31] [32] Similar to these researches, we observed increased TNF-a, IL-1b, IL-6 and IL-17 production in bleomycin-induced pulmonary brosis while PD inhibited the increased production of these inammation cytokines induced by bleomycin. Specially, the level of proinammatory factor (TNF-a) was strongly reduced by PD, this was in accordance with many other reports. 10, 33, 34 Besides, the adding of TNF-a counteracted PD-induced NLRP3 inamma-some inactivation via enhancing NF-kB pathway. 35 These researches hent that PD may interact with TNF-a. This speculation will be examined in our next research. Our results demonstrated that PD relieved pulmonary brosis through suppressing inammation.
Previous study demonstrated that alveolar epithelial cells acquire the phenotype of broblasts through EMT to promote the development of pulmonary brosis.
9,36 EMT occurred in the lung during brogenesis and suppressing EMT can attenuate pulmonary brosis.
37 TGF-b is considered as one of the most potent inducers of broblast activation and pulmonary brosis pathogenesis. 38 In our in vitro experiments, TGF-b was used to induce brosis in HFL-1 cells. We found that TGF-b induced EMT in HFL-1 cells through promoting cell migration, decreasing E-cadherin expression and increasing Vimentin expression. However, PD suppressed TGF-b induced EMT in HFL-1 cells in a dose-dependent manner, indicating that PD relieved pulmonary brosis through suppressing EMT. TGF-b initiates tissue brosis progression mainly via the Smad2 and Smad3 signaling pathways.
39 TGF-b can promote Smad2/3 phosphorylation, which then enhances the combination with Smad4. The Smad2/3/4 complex moves to the nucleus and regulates the transcription of ECM genes, thus enhancing collagen and bronectin synthesis and promoting pulmonary brosis development. 40 In the present study, we also observed that TGF-b increased the ratios of p-Smad2/Smad2 and p-Smad3/ Smad3, suggesting that TGF-b induces brosis in HFL-1 cells through activating TGF-b/Smad signaling pathway. PD was found to block TGF-b/Smad signaling pathway in TGF-b treated HFL-1 cells dose-dependently. Apart from TGF-b pathway, the inhibition of PERK signaling and NF-kB signaling pathway were also involved in the suppression of inammation and brosis in lung. 41 The expression of these pathway proteins treated by PD will be measured in our next research.
Conclusion
Taken together, the present study demonstrated that PD treatment attenuated bleomycin-induced pulmonary brosis in a dose-dependant manner. The benecial effect of PD was possibly related to the inhibition of inammation and EMT through suppressing of TGF-b/Smad signaling pathway. Our nding suggested that PD might be a potential therapeutic candidate in the treatment of pulmonary brosis.
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